Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Drugs in Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cholangitis – Drugs in Development, 2021, provides an overview of the Primary Biliary Cholangitis (Gastrointestinal) pipeline landscape.

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cholangitis – Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Primary Biliary Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 6, 4, 1 and 7 respectively.

Primary Biliary Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cholangitis (Gastrointestinal).

– The pipeline guide reviews pipeline therapeutics for Primary Biliary Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Primary Biliary Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Primary Biliary Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cholangitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cholangitis (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Primary Biliary Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AbbVie Inc

Abcuro Inc

Alexion Pharmaceuticals Inc

Avolynt Inc

Cadila Healthcare Ltd

Calliditas Therapeutics AB

Chia Tai Tianqing Pharmaceutical Group Co Ltd

CymaBay Therapeutics Inc

Dr. Falk Pharma GmbH

Future Medicine Co Ltd

Genfit SA

GenKyoTex SA

Gilead Sciences Inc

GlaxoSmithKline Plc

Hanmi Pharmaceuticals Co Ltd

HighTide Therapeutics Inc

Kowa Co Ltd

MediGene AG

Mirum Pharmaceuticals Inc

NGM Biopharmaceuticals Inc

PRISM Pharma Co Ltd

Suzhou Zelgen Biopharmaceutical Co Ltd

Table of Contents

Table of Contents

Introduction

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Overview

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Therapeutics Development

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Therapeutics Assessment

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Companies Involved in Therapeutics Development

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Drug Profiles

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Discontinued Products

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by AbbVie Inc, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Abcuro Inc, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Alexion Pharmaceuticals Inc, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Avolynt Inc, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Cadila Healthcare Ltd, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Calliditas Therapeutics AB, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by CymaBay Therapeutics Inc, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Dr. Falk Pharma GmbH, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Future Medicine Co Ltd, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Genfit SA, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by GenKyoTex SA, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Gilead Sciences Inc, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by GlaxoSmithKline Plc, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by HighTide Therapeutics Inc, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Kowa Co Ltd, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by MediGene AG, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Mirum Pharmaceuticals Inc, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by NGM Biopharmaceuticals Inc, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by PRISM Pharma Co Ltd, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Dormant Projects, 2021

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports